Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma
Open Access
|Apr 2007References
- Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors.London: Martin Dunitz Ltd; 2001. p. 153-67.
- Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.2005;2121-43.
- Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.1994;2457-66.
- Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.2003;520-35.
- Maloney DG. Mechanisms of action of rituximab.2001;S1-S4.
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas.1999;1244-53.
- Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.2003;7359-68.
- Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, Zelante L, et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.2005;273-86.
- Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.2005;103
- Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.2005;264-76.
- Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.2000;443-.
- Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.1994;435-45.
- Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis.2000;3900-8.
- Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).1999;2217-24.
- Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma.1993;987-94.
Language: English
Page range: 23 - 32
Published on: Apr 30, 2007
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2007 Barbara Novaković, Vladimir Kotnik, Tanja Šetina, Marjeta Vovk, Srdjan Novaković, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.